Carnrite Ventures

Today, we’re announcing a new strategic investment round of $12 million, increasing our total amount raised so far to over $42 million. This latest round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures and TruVenturo GmbH. Additionally, Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures will join the board of directors. Rune Labs CEO Brian Pepin said: “Since launching in 2021, Rune Labs’ StrivePD software has become the most widely used software by Parkinson’s patients and clinicians, and we have built complementary business lines that leverage our network and data to support both clinical development and comprehensive care management. With over 25 years of experience, Jordi brings deep knowledge in building businesses and products and the intersection of data and healthcare. This strategic partnership with Nexus NeuroTech Ventures is in line with our use of modern AI tools to support patients, clinicians, and our pharma partners, and speaks to our ambition to have a deep impact in the way Parkinson’s is understood and treated.” This funding will help propel Rune Labs with our breakthrough technologies that are changing the way people with Parkinson’s monitor their symptoms and live their lives. In 2022, our StrivePD software ecosystem for Parkinson’s disease was granted 510(k) clearance by the FDA to collect patient symptom data, including #tremor and #dyskinesia, via Apple Watch. Since then, we’ve continued to grow and establish partnerships on our path to revolutionizing precision neurology technology. https://lnkd.in/dvn_Hzq9 #Parkinsons #braindata #digitalhealth #healthtechnology #parkinsonsdisease #funding #fundraising #NexusNeuroTech #investment #businessgrowth